Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process

REFERENCES

• Substance Abuse and Mental Health Services Administration (SAMHSA), US Department of Health and Human Services. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: SAMHSA; 2013.
   Google Scholar
• American Psychiatric AssociationF. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
   Google Scholar
• Becker WC, Fiellin DA, Merrill JO, et al. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend. 2008; 94:207–213.
   PubMed Web of Science ®Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, et al. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011; 13:374–391.
   PubMed Web of Science ®Google Scholar
• American Methadone Treatment Association. Methadone Maintenance Program and Patient Census in the U.S. New York: American Methadone Treatment Association; 1998.
   Google Scholar
• Arfken CL, Johanson CE, di Menza S, et al. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;; 39:96–104.
   PubMed Web of Science ®Google Scholar
• Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008; 3:17.
   PubMed Web of Science ®Google Scholar
• O’Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998; 105:100–105.
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Chawarski M, O’Connor PG, et al. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005;; 79:113–116.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Fiellin DA, Friedmann PD, et al. Update in addiction medicine for the primary care clinician. J Gen Intern Med. 2008; 23:2112–2116.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Trafton JA, Saxon AJ, et al. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Depend. 2007; 90:292–296.
   PubMed Web of Science ®Google Scholar
• Ling W, Jacobs P, Hillhouse M, et al. From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat. 2010; 38(Suppl 1):S53–S60.
   PubMedGoogle Scholar
• Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011; 36:584–589.
   PubMed Web of Science ®Google Scholar
• Stein BD, Gordon AJ, Sorbero M, et al. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012; 123:72–78.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Liberto J, Granda S, et al. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008; 17:459–462.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Liberto J, Granda S, et al. Physician training is never a failure. Am J Addict. 2009;; 18:337–338.
   Web of Science ®Google Scholar
• Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011; 25:215–224.
   PubMed Web of Science ®Google Scholar
• Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010; 25:936–941.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Kunins HV, Roose RJ, et al. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007; 22:1325–1329.
   PubMed Web of Science ®Google Scholar
• Hutchinson E, Catlin M, Andrilla CH, et al. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014; 12:128–133.
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Wunsch MJ, Nuzzo PA, et al. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat. 2011; 41:321–329.
   PubMed Web of Science ®Google Scholar
• Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009; 36:244–251.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Connery HS, Ellison TV, et al. Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency. Am J Addict 2014; 23:618–622.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
   Google Scholar
• McNicholas L. Personal communication to Bradley D. Stein; 2011.
   Google Scholar
• Center for Substance Abuse Treatment. Buprenorphine: A Guide for Nurses. Washington, DC: Substance Abuse and Mental Health Services Administration; 2009. DHHS Publication No. (SMA) 09-4376.
   Google Scholar
• Department of Veteran's Affairs. VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders. Washington, DC: US Department of Defense; 2009.
   Google Scholar
• Department of Veteran's Affairs Affairs. VA/DoD Clinical Practice Guideline for Management of Substance Use Disorder (SUD). Washington, DC: US Department of Defense; 2009.
   Google Scholar
• Vermont Department of Health Division of Alcohol and Drug Abuse Programs (VDH/ADAP), Office of Vermont Health Access (OVHA). Vermont Buprenorphine Practice Guidelines. Morrisville, VT: Author; 2010.
   Google Scholar
• Goodman F, Gordon A, Kivlahan D, et al. Criteria for Use of Buprenophine/Naloxone and Buprenorphine Sublingual Tablets. Washington, DC: VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel, Department of Veterans Affairs; 2007.
   Google Scholar
• Stein BD, Sorbero MJ, Goswami U, et al. Impact of a private health insurance mandate on public sector autism service use in Pennsylvania. J Am Acad Child Adolesc Psychiatry. 2012; 51:771–779.
   PubMed Web of Science ®Google Scholar
• Shuster J. Community care behavioral health organization [personal communication]; 2011.
   Google Scholar
• Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA:RAND Corporation; 2001.
   Google Scholar
• McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing colorectal cancer surgery. J Natl Cancer Inst. 2006; 98:1623–1633.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004; 61:807–816.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996; 66:17–31.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996;(30):17–30.
   PubMedGoogle Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264:2511–2518.
   PubMed Web of Science ®Google Scholar
• Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011; 5:254–263.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Dietze P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007; 102:616–622.
   PubMed Web of Science ®Google Scholar
• Rotter T, Kinsman L, James E, et al. The effects of clinical pathways on professional practice, patient outcomes, length of stay, and hospital costs: Cochrane systematic review and meta-analysis. Eval Health Prof. 2012; 35:3–27.
   PubMed Web of Science ®Google Scholar
• Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013; 22:574–580.
   PubMed Web of Science ®Google Scholar
• Crabtree BL, Dostrow VG, Evans CJ, et al. Outcome assessment of an antipsychotic drug algorithm: effects of the Mississippi State Hospital algorithm project. Psychiatric Serv. 2011; 62:963–965.
   PubMed Web of Science ®Google Scholar
• Miller AL, Crismon ML, Rush AJ, et al. The Texas Medication Algorithm Project. Schizophr Bull. 2004; 30:627–647.
   PubMed Web of Science ®Google Scholar
• Stevens J, Kelleher KJ, Wang W, et al. Use of psychotropic medication guidelines at child-serving community mental health centers as assessed by clinic directors. Community Mental Health J. 2011; 47:361–363.
   PubMed Web of Science ®Google Scholar
• Gagliardi AR, Brouwers MC, Palda VA, et al. How can we improve guideline use? A conceptual framework of implementability. Implement Sci. 2011; 6:26.
   PubMed Web of Science ®Google Scholar
• Shekelle P, Woolf S, Grimshaw JM, et al. Developing clinical practice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; and the emerging issues of enhancing guideline implementability and accounting for comorbid conditions in guideline development. Implement Sci. 2012; 7:62.
   PubMed Web of Science ®Google Scholar
• Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007; 1:62–67.
   PubMed Web of Science ®Google Scholar
• Koch AL, Arfken CL, Schuster CR. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 27 2006;. 83:274–278.
   PubMed Web of Science ®Google Scholar
• Maxwell JC. Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators. Substance Abuse and Mental Health Services Administration; 2006. Available at: http://buprenorphine.samhsa.gov.
   Google Scholar
• Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011; 4:28–41.
   PubMedGoogle Scholar
• Sohler NL, Li X, Kunins HV, et al. Home-versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2010; 38:153–159.
   PubMed Web of Science ®Google Scholar